Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

KX-826 is available on Amazon but not shipped to the Netherlands. The user seeks advice on obtaining it in Europe.

The conversation is about finding a reliable source for CB 03-01 as an alternative treatment for hair loss due to intolerance to finasteride and RU58841. The user is also considering minoxidil for temporary effectiveness.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.

The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.

A 21-year-old experienced erectile dysfunction after using finasteride and consuming multiple drugs, including MDMA, LSD, and weed. He plans to quit finasteride and weed, improve his habits, and consider alternative treatments like mesotherapy with dutasteride.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

The conversation is about finding a reliable source for RU58841 in middle Europe, as the user had issues with previous suppliers. Anageninc is suggested as a potential source.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The user experienced hair improvement using 1mg finasteride daily for six months, managing seborrheic dermatitis with rosemary and eucalyptus oil. They are considering switching to dutasteride for potentially better results.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Someone looking for solutions to their hair loss, who has tried and failed to tolerate anti-androgen treatments such as finasteride, CB-03-01, RU58841, and Eucapil. The user is seeking advice and understanding of their extreme sensitivity to these treatments.

A user started taking 0.25mg of finasteride every other day to prevent hair loss and documented their experience. Initially, they felt anxious and had headaches, but by the second week, they felt normal with no side effects or changes in hair.

PP405 is being discussed as a promising hair loss treatment, potentially effective when combined with minoxidil and pyrilutamide. Some users are skeptical about rapid hair regrowth claims, while others are considering alternatives like GT20029 and pyrilutamide instead of finasteride.

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

The conversation discusses reliable brands for RU58841, with recommendations for RUdirect and Receptorchem. Users also mention Anageninc as a known option for RU58841 in Europe and the UK.

Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.